Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftaroline fosamil versus vancomycin plus aztreonam for complicated bacterial skin and soft tissue infections
2011-004013-16Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2012
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in skin and soft tissue infections (SSTIs) comparing Ceftaroline fosamil with Vancomycin plus aztreonam (2 arms). Primary endpoint: Clinical cure rate at test of cure. Started Mar 2012; status: completed.
02
Drugs
ceftaroline fosamilvancomycinaztreonam
03
Conditions
skin and soft tissue infections (SSTIs)
Beyond the preview
Go deeper on 2011-004013-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004013-16.